Ascendia

  MARKET NEWS

Guangzhou Bio-gene Technologies Announces Initiation of Phase 1 Clinical Trial for CAR-T Targeting CLL-1
Allarity Therapeutics’ Stenoparib Shows Clear Clinical Benefit & Achieves Significant Milestone With Early Conclusion of Phase 2 Trial in Advanced Ovarian Cancer
Pluri Launches Novel Immunotherapy Platform for Solid Tumor Treatment
ASLAN Pharmaceuticals Announces Expansion of its Collaboration With Zenyaku to Investigate the Biology Underlying Differential Effects of Eblasakimab Compared to Other Biologics
INmune Bio Provides Update on Two Patients From Phase 1b Alzheimer’s Disease Trial Who Continue to Receive XPro Under Compassionate Use for Over 3 Years
Editas Medicine & Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration

  FEATURED EDITORIAL

  COMPANY PROFILE

Experic, a contract development and manufacturing organization (CDMO) and clinical trial supply services company, supports every phase of a product’s life cycle from conception to clinical and commercial scale, across a range of dosing and packaging formats. While being a specialized inhalation CDMO, we provide drug product development and manufacturing expertise across a variety of modalities from early phase development to clinical and commercial packaging and labeling. Leveraging our state-of-the-art cGMP facility, we manage global delivery of the highest quality products and services, even for expedited projects, while providing unparalleled knowledge, expertise, and customer service. Click here for more.

  EXCLUSIVE ONLINE CONTENT

Medigene AG Expands Patent Portfolio With Patent Grant for its Targeted T Cell Receptor

Medigene AG Expands Patent Portfolio With Patent Grant for its Targeted T Cell Receptor

Medigene AG recently announced it has been issued a patent by the European Patent Office protecting its T cell receptor (TCR) targeting NY-ESO-1….

Altamira Therapeutics Announces Filing of Provisional Patent Application for OligoPhore Nanoparticles With siRNA Targeting p65 Protein in Treatment of Cancer & Inflammation

Altamira Therapeutics Announces Filing of Provisional Patent Application for OligoPhore Nanoparticles With siRNA Targeting p65 Protein in Treatment of Cancer & Inflammation

Altamira Therapeutics Ltd. recently announced it has filed a provisional patent application with the United States Patent Office (USPTO) which covers nanoparticles comprising the….

Adare Expands Global High Potency Handling & Packaging Capabilities

Adare Expands Global High Potency Handling & Packaging Capabilities

Adare Pharma Solutions, a global technology-driven CDMO specializing in oral dosage forms, recently announced expansions of its high potency handling capabilities in the….

Biotts Becomes First Company to Successfully Deliver Insulin Through Skin

Biotts Becomes First Company to Successfully Deliver Insulin Through Skin

Patients with Type 1 diabetes could replace up to 20 insulin injections over a period of five days….

Lonza Launches AI-Enabled Route Scouting Service to Accelerate Small Molecule Development

Lonza Launches AI-Enabled Route Scouting Service to Accelerate Small Molecule Development

New advanced technology-enabled offering aims to streamline synthetic route identification for novel active pharmaceutical ingredients (APIs)….

Deciphera Pharmaceuticals to be Acquired by ONO Pharmaceutical for .4 Billion

Deciphera Pharmaceuticals to be Acquired by ONO Pharmaceutical for $2.4 Billion

Deciphera’s kinase inhibitor expertise and established commercialization platform in key markets will reinforce ONO Pharmaceutical’s pipeline and accelerate global reach….

  WHITEPAPERS & WEBINARS

WHITEPAPER - Continuous Flow - An Emerging Alternative

WHITEPAPER - Continuous Flow - An Emerging Alternative

Pharmaceutical companies have traditionally been risk-averse, often adopting safe and well-established processes due to the conservative stance of regulatory agencies on novel methodologies. However, with the increasing complexity of drug molecules and the demand for newer and harsher reaction conditions, …

WHITEPAPER - The Viscosity Reduction Platform: Viscosity-Reducing Excipients for Protein Formulation

WHITEPAPER - The Viscosity Reduction Platform: Viscosity-Reducing Excipients for Protein Formulation

Protein viscosity is one of the major obstacles in preparing highly concentrated protein formulations suitable for subcutaneous (subQ) injection. SubQ application of highly concentrated protein formulations enables a higher patient convenience and might thus lead to reduction in health costs. …

WHITE PAPER: HPAPI Drug Solid Oral Dosage (SOD) Manufacturing – Ensuring Content Uniformity

WHITE PAPER: HPAPI Drug Solid Oral Dosage (SOD) Manufacturing – Ensuring Content Uniformity

What techniques should manufacturers employ when working with low-dose drug products?

By: Thomas Daggs, MBA, Vice President, Product Development & Quality Control, and Angelo Consalvo, Director of Manufacturing, Enteris BioPharma

Anyone who takes an oral tablet medication – whether prescribed …

WHITEPAPER - Must-Use Strategies to Successfully Transfer & Scale Your Pharmaceutical Product

WHITEPAPER - Must-Use Strategies to Successfully Transfer & Scale Your Pharmaceutical Product

Introduction

Pharmaceutical companies are turning more frequently to external manufacturing partners for their development and production needs. A cornerstone of modern drug development strategy, contract development and manufacturing organizations (CDMOs) now produce about 28% of the world’s prescription and non-prescription …

WHITEPAPER - Manufacturing of 10-mg Loratadine Self-Emulsifying Drug Delivery System (SEDDS) Tablets by Direct Compression With ABISORB-DC & ABISOL Emulsion Preconcentrate Kit

WHITEPAPER - Manufacturing of 10-mg Loratadine Self-Emulsifying Drug Delivery System (SEDDS) Tablets by Direct Compression With ABISORB-DC & ABISOL Emulsion Preconcentrate Kit

Traditionally, lipid-based drug delivery, including SEDDS, for per-oral dosing have primarily been formulated as soft-gels or liquid-filled hard-gels. With ABISORB-DC, the bioavailability enhancing features of lipid-based drug delivery can be combined with the high-throughput and ease of manufacturing of direct …

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

May 15 – Injection Devices
May 22 – Parenteral Contract Manufacturing